Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells

Inclusion Criteria: 1.Understanding the whole process of the study, voluntary participation and signed the informed consent; 2.18 Years to 65 Years old, Body Mass Index (BMI) between 18.5-35; 3.Diagnosed according to biopsy for Psoriasis vulgaris for more than 6 months and resistance to phototherapy, systemic therapy, or a combination of these therapies,BSA(body surface area)\>10%, PGA≥3 and PASI\>10 at baseline; 4. Patients participated in any stem cell therapy within 6 months; Exclusion Criteria: 1. WBC(white blood cell count ) \<3.5x109/L, blood platelet count\<100x109/L, hemoglobin\<100g/L serum creatinine\>1.5 x ULN(upper limit of normal), bilirubin \> 1.5 x ULN(upper limit of normal), AST(SGOT,glutamic-oxalacetic transaminase)/ALT(SGPT,glutamic-pyruvic transaminase) \>2.0 x ULN(upper limit of normal);Either HIV-antibody(human immunodeficiency virus-antibody), HBV-antibody (hepatitis B virus-antibody ) or syphilis antibody is positive; 2. Have a serious heart, lung, kidney and other vital organs and endocrine system lesions and the history,Patients suffering from any acute or chronic infectious diseases, patients suffering from malignant tumor; Mental disorders, history of alcohol abuse, drug or other substance abuse; 3. Patients who have received systemic therapy within recent one month or topical therapy in two weeks; 4. Having a serious allergic history or being allergic to two or more than 2 kinds of food or drugs; 5. Pregnant women, or women who ready for pregnancy or lactating; Patients participated in any clinical trials within 3 months; Other cases which researchers believe that can not enroll.